Navigation Links
Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Date:11/15/2011

SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has priced an underwritten public offering of 19,000,000 shares of its common stock at a price to the public of $3.75 per share.  The net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.4 million.  Cadence has granted the underwriters for the offering a 30-day option to purchase up to an additional 2,800,000 shares of common stock to cover over-allotments, if any.  The offering is expected to close on or about November 18, 2011, subject to customary closing conditions.

Deutsche Bank Securities Inc. is acting as sole book-running manager, Leerink Swann LLC is acting as co-lead manager and Cowen and Company, LLC is acting as co-manager for the offering. The securities described above are being offered by Cadence pursuant to a shelf registration statement that has been previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311-3901, or by telephone at: (800) 503-4611, or by email at: prospectus.cpdg@db.com.  This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, but are not limited to, statements regarding the completion, timing and size of the public offering, and the expected net proceeds therefrom.  Actual results may differ materially from those set forth in this press release due to the risks and uncertainties, including, without limitation, those associated with market conditions and the satisfaction of customary closing conditions related to the public offering, as well as those inherent in Cadence's business and finances in general, including the risks detailed in Cadence's prior press releases as well as in Cadence's periodic and other public filings with the SEC.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.  Contact:

William R. LaRue

Kelli FranceSVP & Chief Financial Officer

Media RelationsCadence Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... , May 23, 2016 The ... USD 5.0 billion by 2022, according to a new ... of medical waste coupled with the lack of centralized ... expected to drive the demand for reprocessed medical devices ... as compared to that of the original device is ...
(Date:5/22/2016)... DUBLIN , May 23, 2016 ... to develop its anti-fibrotic and anti-inflammatory compound DS102 ... well as in non-alcoholic steatohepatitis (NASH) patients. ... is significantly sequestered in lung tissue and has ... tissue after oral administration. The Company will publish ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... 2016 , ... Global Lyme Alliance (GLA), a leading nonprofit ... has named Scott Santarella as its new CEO. , Santarella is former ... San Francisco, where he successfully helped to grow the organization from a regional ...
(Date:5/24/2016)... ... May 24, 2016 , ... Researchers ... of protocols designed to reduce bleeding complications from percutaneous coronary intervention (PCI). The ... Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted bleeding event ...
(Date:5/24/2016)... ... May 24, 2016 , ... Design Concepts ... ‘El Centro del Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was ... offer something special for this often overlooked neighborhood. Located at 609 E. 6th ...
(Date:5/24/2016)... ... May 24, 2016 , ... Celebration is in ... kicked off its 5th Annual Photo Contest. The label contest is underway, and ... year's prizes include a GoPro Hero4, a 40-inch high-definition flat-screen television, an Apple ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... On the ... took the time to summarize the weight loss process: , New patients have a ... Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There are 15 ...
Breaking Medicine News(10 mins):